Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema).
Methods
Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum.
Results
Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions.
Conclusions
These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
References
1.
AmannaI.J., SlifkaM.K., CrottyS.Immunity and immunological memory following smallpox vaccination. Immunol Rev2006; 211: 320–337.
2.
GreenbergR.N., KennedyJ.S.ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs2008; 17: 555–564.
3.
GrosenbachD.W., BerhanuA., KingD.S.Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A2010; 107: 838–843.
4.
HugginsJ., GoffA., HensleyL.Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother2009; 53: 2620–2625.
5.
ParkerS., TouchetteE., OberleC.Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res2008; 77: 39–49.
6.
McCauslandM.M., BenhniaM.R., CrickardL.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther2010; 15: 661–675.
7.
BenhniaM.R., McCauslandM.M., LaudenslagerJ.Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol2009; 83: 12355–12367.
8.
ChenZ., EarlP., AmericoJ.Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol2007; 81: 8989–8995.
9.
ChenZ., EarlP., AmericoJ.Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A2006; 103: 1882–1887.
10.
FennerF., HendersonD.A., AritaI., JezekZ., LadnyiI.D.Smallpox and its eradication.Geneva: World Health Organization1988; Chapter 4.
11.
FulginitiV.A., PapierA., LaneJ.M., NeffJ.M., HendersonD.A.Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis2003; 37: 241–250.
12.
FulginitiV.A., PapierA., LaneJ.M., NeffJ.M., HendersonD.A.Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis2003; 37: 251–271.
13.
WittekR.Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis2006; 10: 193–201.
14.
HopkinsR.J., LaneJ.M.Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis2004; 39: 819–826.
15.
DaviesD.H., MolinaD.M., WrammertJ.Proteomewide analysis of the serological response to vaccinia and smallpox. Proteomics2007; 7: 1678–1686.
16.
DaviesD.H., McCauslandM.M., ValdezC.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol2005; 79: 11724–11733.
17.
BenhniaM.R., McCauslandM.M., SuH.P.Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol2008; 82: 3751–3768.
18.
BenhniaM.R.-E-I, McCauslandM.M., MoyronJ.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol2009; 83: 1201–1215.
19.
MatsudaH., WatanabeN., GebaG.P.Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol1997; 9: 461–466.
20.
KawakamiY., YumotoK., KawakamiT.An improved mouse model of atopic dermatitis and suppression of skin lesions by an inhibitor of Tec family kinases. Allergol Int2007; 56: 403–409.
21.
KawakamiY., TomimoriY., YumotoK.Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med2009; 206: 1219–1225.
22.
MossB.Poxviridae: the viruses and their replication. In KnipeD., HowleyP., GriffinD., LambR. (Editors). Fundamental Virology. 5th ed.Philadelphia: Lippincott2006; pp. 2849–2884.
23.
LustigS., FoggC., WhitbeckJ.C., MossB.Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology2004; 328: 30–35.
24.
SmithG.L., VanderplasschenA., LawM.The formation and function of extracellular enveloped vaccinia virus. J Gen Virol2002; 83: 2915–2931.
25.
LawM., CarterG.C., RobertsK.L., HollinsheadM., SmithG.L.Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc Natl Acad Sci U S A2006; 103: 5989–5994.
